These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28464765)

  • 21. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.
    Gribkoff VK; Kaczmarek LK
    Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
    Bishop KM
    Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zebrafish models in neuropsychopharmacology and CNS drug discovery.
    Khan KM; Collier AD; Meshalkina DA; Kysil EV; Khatsko SL; Kolesnikova T; Morzherin YY; Warnick JE; Kalueff AV; Echevarria DJ
    Br J Pharmacol; 2017 Jul; 174(13):1925-1944. PubMed ID: 28217866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adult neurogenesis pharmacology in neurological diseases and disorders.
    Taupin P
    Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Securing the future of drug discovery for central nervous system disorders.
    Andersen PH; Moscicki R; Sahakian B; Quirion R; Krishnan R; Race T; Phillips A;
    Nat Rev Drug Discov; 2014 Dec; 13(12):871-2. PubMed ID: 25435203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges in developing drugs for neurological and psychiatric disorders.
    Simon NG; Brownstein MJ
    Prog Neurobiol; 2017 May; 152():1-2. PubMed ID: 28442128
    [No Abstract]   [Full Text] [Related]  

  • 30. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
    Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T
    Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Animal models of CNS disorders.
    McGonigle P
    Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery.
    Mayol-Llinàs J; Farnaby W; Nelson A
    Chem Commun (Camb); 2017 Nov; 53(91):12345-12348. PubMed ID: 29099137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.
    Geerts H; Kennis L
    Future Med Chem; 2014; 6(16):1757-69. PubMed ID: 25574530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in the Development of Pyrimidine-based CNS Agents.
    Pant S; Nain S
    Curr Drug Discov Technol; 2023; 20(2):e031022209428. PubMed ID: 36200187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Potentially CNS-active tricyclic compounds with a bridged central ring. 3. Synthesis of partially hydrogenated 9,10-epithioanthracenes].
    Linde HF; Krämer NH
    Arch Pharm (Weinheim); 1990 May; 323(5):295-9. PubMed ID: 2383172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.